Navigation Links
Max Planck Innovation awards license for actin marker LifeAct
Date:7/26/2010

Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, awards an exclusive license for LifeAct to ibidi GmbH, a provider of cell analysis products, located in Martinsried near Munich. The novel peptide allows for actin, an important protein, to be made visible in living cells without disturbing the actin dependent processes. Therefore, cells as well as the development of various diseases can be better researched.

All higher cells depend on their cytoskeleton. This extremely flexible and highly dynamic structure gives the cells its shape, but is also an essential component in cell division as well as other fundamental processes of life. As a structural protein, actin is a component of the cytoskeleton, which can form elongated filaments that are used as supply routes for molecular loads in the cell among other things. Thereby, actin plays an important role in a wide array of functions such as in the development of organs and the movement of cells. Defects in the cytoskeleton are associated with various diseases such as polycystic kidney diseases and invasive tumors. Thus, the study of the cytoskeleton and in particular the study of actin is a priority in the biomedical research.

In the past, markers were available that allowed visualization of actin, but also interfered with its activity. Whereas the actin marker LifeAct, now licensed by ibidi, attaches itself to the structural protein without limiting its function. LifeAct, only 17 amino-acids long, is linked to a fluorescent dye, which makes it possible to follow the development and movement in living cells. The marker has already been used successfully in yeast cells, kidney cells, white blood cells, neuron and a variety of other cell types and tissues. A research team led by the biologists Dr. Roland Wedlich-Sldner and Dr. Michael Sixt from the Max Planck Institute for Biochemistry developed the marker. In future, ibidi will offer the peptide in various products for biological analysis. Even pathological processes where actin is involved could be decoded.

"LifeAct fits perfectly into our product portfolio with cell microscopy, immunofluorescence and cell based assays" emphasizes Dr. Valentin Kahl, founder and CEO of ibidi. "With help of the marker, our customers can visualize and quantify the movement of cells. The new technology will be of great benefit, especially in studies of angiogenesis (the formation of blood vessels), but also in oncology, neurology, and immunology." Moreover, Dr. Mareike Gritz, patent and license manager at Max Planck Innovation, sees a great advantage in the proximity of Max Planck Institute for Biochemistry and Neurobiology to ibidi GmbH in Martinsried: " The mutual support and uncomplicated communication should ensure a close cooperation and hence a rapid market implementation of LifeAct." This should benefit the researchers and product developers as well as the research community. Thus, LifeAct opens unprecedented opportunities to research actin as an essential component of life's fundamental processes.


'/>"/>

Contact: Markus Berninger, Max-Planck-Innovation GmbH
Markus.Berninger@max-planck-innovation.de
49-089-290-91930
Max-Planck-Gesellschaft
Source:Eurekalert  

Related biology news :

1. Innovation and current status of prostate cancer gene therapy featured in Human Gene Therapy
2. NY state the focus of Congressional hearing on how research and innovation fuel local economies
3. ACS Webinar focuses on green chemistry innovations and applications
4. Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference
5. EPA awards more than $1 million to college teams for environmental innovation
6. Research & Entrepreneurship Day 2010: Engineering Innovation
7. Innovation in science
8. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
9. Oberthur Technologies Receives Product Innovation Award
10. Leaders from the National Academies gather to discuss engineering innovations in health care
11. Innovation boost to tackle climate change
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Max Planck Innovation awards license for actin marker LifeAct
(Date:1/6/2017)... , Jan. 6, 2017  Privately-held CalciMedica, ... studies in healthy volunteers of a novel calcium ... treat acute pancreatitis. Acute pancreatitis, ... a mild disorder, but can be very serious.  In ... and sepsis, where extended hospital stays, time in ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at this ... leader in connected health and biometric measurement devices and services, will be ... On display in A&D Medical,s special CES Exhibit Suite , ... ongoing expansion of the company,s WellnessConnected product platform.  ... ...
(Date:12/22/2016)... Calif. , Dec. 20, 2016  As part of ... 23andMe, the leading personal genetics company, recently released its latest ... . The book focuses on the topics of inheritance ... Generation Science Standards (NGSS) taught in elementary school classrooms in ... in a series by illustrator Ariana Killoran , whose ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... ... 23, 2017 , ... AxioMed will be presenting its viscoelastic ... in Montego Bay, Jamaica from January 26-28th. “We’re excited to be presenting the ... experience the simplicity of the surgical technique,” said Jake Lubinski, President of AxioMed. ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L ... the healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices ... and scientific consultants and contractors. This is the latest step in G&L’s expansion ...
(Date:1/21/2017)... ... January 21, 2017 , ... Nova Oculus Partners ... a pioneering medical device for the treatment of Age-Related Macular Degeneration. , The ... a global regulatory consultancy that helps companies like ours secure government approvals for ...
(Date:1/21/2017)... Jan. 20, 2017 Bioptix, Inc. ... announced that on January 14, 2017 the Board of ... the Company will terminate certain employees associated with the ... The Company commenced terminations on January 16, 2017 and ... The Company may pay severance benefits in certain circumstances ...
Breaking Biology Technology: